CARDIOVASCULAR MEDICINE

Progression of familial and non-familial dilated cardiomyopathy: long term follow up

V V Michels¹, D J Driscoll², F A Miller³, T M Olson^2,*, E J Atkinson⁴, C L Olswold⁴, D J Schaid⁴

¹ Department of Medical Genetics, Mayo Clinic/Foundation, Rochester, Minnesota, USA
² Pediatric and Adolescent Medicine, Mayo Clinic/Foundation
³ Internal Medicine, Mayo Clinic/Foundation
⁴ Health Sciences Research, Mayo Clinic/Foundation

Correspondence to:
Correspondence to:
Dr Virginia V Michels, Department of Medical Genetics, Mayo Clinic, 200 1 St SW, Rochester, MN 55905, USA;
michels.virginia{at}mayo.edu

Background: It is unknown whether progression of familial idiopathic dilated cardiomyopathy differs from progression in the non-familial form. It has been suggested that familial disease indicates a worse prognosis, and that this should be considered when planning the timing of heart transplantation.

Objective: To compare five year survival or time to heart transplantation in an unselected series of patients with dilated cardiomyopathy who had been evaluated for familial v non-familial disease through the echocardiographic investigation of first degree relatives.

Design: Medical records were reviewed and questionnaires were mailed to all patients who had previously participated in a family based study of dilated cardiomyopathy. Information was gathered about survival, heart transplantation, and left ventricular ejection fraction (LVEF) measurements. Survival data were censored at the time of cardiac transplantation.

Results: Follow up data were obtained for 99 of 101 patients (69 with non-familial and 30 with familial disease). Five year survival was 55% for non-familial and 51% for familial patients (NS). The main predictor of mortality was an LVEF of < 30%. Familial status did not predict mortality. There was no significant difference in follow up LVEF values between the groups.

Conclusions: Five year survival is not significantly different in the familial and non-familial forms of dilated cardiomyopathy.

Keywords: dilated cardiomyopathy; prognosis; familial dilated cardiomyopathy

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Hess, O. M., McKenna, W., Schultheiss, H.-P. (2009). CHAPTER 18 Myocardial Disease. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• van Tintelen, J. P., Tio, R. A., Kerstjens-Frederikse, W. S., van Berlo, J. H., Boven, L. G., Suurmeijer, A. J.H., White, S. J., den Dunnen, J. T., te Meerman, G. J., Vos, Y. J., van der Hout, A. H., Osinga, J., van den Berg, M. P., van Veldhuisen, D. J., Buys, C. H.C.M., Hofstra, R. M.W., Pinto, Y. M. (2007). Severe Myocardial Fibrosis Caused by a Deletion of the 5' End of the Lamin A/C Gene. J Am Coll Cardiol 49: 2430-2439 [Abstract] [Full Text]  
• Burkett, E. L., Hershberger, R. E. (2005). Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45: 969-981 [Abstract] [Full Text]  
• Negro, A., Brar, B. K., Lee, K.-F. (2004). Essential Roles of Her2/erbB2 in Cardiac Development and Function. Recent Prog Horm Res 59: 1-12 [Abstract] [Full Text]